Rethinking Market Strategy within a Patient-Centric Era

EP: 1.Industry Voices on Current Pricing and Reimbursement Models

EP: 2.Navigating Regulatory Barriers within Market Access

EP: 3.Effective Real-World Evidence for Adding Value to a Clinical Trial

EP: 4.Harmonizing the Payer Perspective with Real-World Evidence

EP: 5.Challenges for Bringing Orphan Drugs to Market

EP: 6.Strategies in Today’s Market for Pricing and Reimbursement Models

EP: 7.The Ins and Outs of Value-Based Contracts: Timing, Evidence, and Risk Alignment

EP: 8.How New Policies are Impacting Market Sustainability

Now Viewing

EP: 9.Rethinking Market Strategy within a Patient-Centric Era

As the series closes, the panel reflects on an often underrepresented but crucial stakeholder: the patient. The discussion underscores the need for a more patient-centered market access strategy—one that incorporates health equity, diagnostic and treatment journey support, and clearer communication around cost and adherence.

Key discussion topics include:

• How social determinants of health (SDOH) shape real-world treatment access.
• The growing need for payer transparency and patient trust in the marketplace.
• Strategies to engage patients early in development to ensure success.